Literature DB >> 19575689

Acceptability of a carrageenan-based candidate vaginal microbicide and matching placebo: findings from a phase II safety trial among women in Chiang Rai, Thailand.

Heidi E Jones1, Supaporn Chaikummao, Janneke H H M van de Wijgert, Barbara A Friedland, Chomnad Manopaiboon, Paisit Witwatwongwana, Mayuree Wankrairot, Nartlada Chantharojwong, Peter H Kilmarx.   

Abstract

OBJECTIVE: To evaluate extended acceptability of vaginal use of a carrageenan-based candidate microbicide and placebo in northern Thai women.
METHODS: As part of a randomized, placebo-controlled, triple-blinded clinical trial, women were asked to insert gel with each vaginal sex act and at least three times per week for 1 year. Used applicators were collected monthly; acceptability questions were asked quarterly.
RESULTS: One hundred sixty-five women were enrolled (83 microbicide, 82 placebo); 148 (90%) remained in the study for 12 months. Gel use was high, with > or =87% returning at least three used applicators per week at each visit. Although acceptability was generally high, some decline in positive reporting was noted in terms of ease of application, timing of gel insertion, and gel volume over time. Approximately one quarter reported gel use increased her sexual pleasure. Over one quarter reported that gel volume of 5 mL was too much. All women with a steady partner at 12 months reported talking to their partner about using the gel. Only 2 women spontaneously mentioned being able to use a product covertly as one of the most appealing attributes of a potential microbicide.
CONCLUSIONS: Although women in this study generally reported high acceptability and use, some found 5 mL of gel to be too much. Focusing on enhanced sexual pleasure and lubrication may be beneficial for marketing proven microbicides. Development of products will need to balance lubrication and efficacy with perceptions of too much volume. The ability to use a product covertly was not a high priority in this population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19575689     DOI: 10.1089/jwh.2008.0862

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  7 in total

Review 1.  The Sexual Acceptability of Contraception: Reviewing the Literature and Building a New Concept.

Authors:  Jenny A Higgins; Nicole K Smith
Journal:  J Sex Res       Date:  2016-03-08

2.  Using integrated mixed methods to develop behavioral measures of factors associated with microbicide acceptability.

Authors:  Kathleen M Morrow; Rochelle K Rosen; Liz Salomon; Cynthia Woodsong; Lawrence Severy; Joseph L Fava; Sara Vargas; Candelaria Barroso
Journal:  Qual Health Res       Date:  2011-03-29

Review 3.  Clinical evaluation of microbicide formulations.

Authors:  Kathleen M Morrow; Craig Hendrix
Journal:  Antiviral Res       Date:  2010-12       Impact factor: 5.970

4.  Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity.

Authors:  Charlene S Dezzutti; Elizabeth R Brown; Bernard Moncla; Julie Russo; Marilyn Cost; Lin Wang; Kevin Uranker; Ratiya P Kunjara Na Ayudhya; Kara Pryke; Jim Pickett; Marc-André Leblanc; Lisa C Rohan
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

5.  Increasing the effectiveness of vaginal microbicides: a biophysical framework to rethink behavioral acceptability.

Authors:  Stéphane Verguet; Bethany Young Holt; Andrew J Szeri
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

6.  Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand.

Authors:  Sara J Whitehead; Catherine McLean; Supaporn Chaikummao; Sarah Braunstein; Wat Utaivoravit; Janneke H van de Wijgert; Philip A Mock; Taweesap Siraprapasiri; Barbara A Friedland; Peter H Kilmarx; Lauri E Markowitz
Journal:  PLoS One       Date:  2011-09-07       Impact factor: 3.240

7.  Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting.

Authors:  Andrew Vallely; Lisa Fitzgerald; Voletta Fiya; Herick Aeno; Angela Kelly; Joyce Sauk; Martha Kupul; James Neo; John Millan; Peter Siba; John M Kaldor
Journal:  BMC Res Notes       Date:  2012-11-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.